Dr. David Young of Kisoji Biotechnology on Antibody Therapeutics and Oncology Innovation

Dr. David Young, CEO of Kisoji Biotechnology, discusses his company’s work in antibody therapeutics to tackle critical challenges in oncology and other diseases. Dr. Young explains what Kisoji Biotechnology does, why the company has a particular focus on cancer treatment, and where some of the biggest advancements have occurred so far in antibody-based treatments and what breakthroughs are reshaping how we think about cancer care and immune response.